Senti Biosciences (SNTI) Stock Price, News & Analysis

Company Overview

Senti Biosciences, Inc. (NASDAQ:SNTI) is a biotechnology company developing programmable cell and gene therapies. Its technology is designed to enable therapeutic cells to detect disease-related signals and respond with a controlled action, with the goal of improving the precision, safety and effectiveness of advanced treatments.

The company’s platform uses synthetic biology and gene circuits to engineer cells with logic-based functions. These circuits can be designed to recognize combinations of biological markers, activate therapeutic payloads and regulate cellular activity. Senti Bio has applied this approach primarily to oncology and has developed investigational programs involving engineered immune cells for the treatment of cancer.

Senti Bio was founded in 2016 and is headquartered in the San Francisco Bay Area. The company has worked with biotechnology and pharmaceutical partners to advance applications of its gene-circuit technology and continues to focus on developing cell therapies for serious diseases. Its products remain investigational and are subject to clinical and regulatory review.

Key Stats

• Today's Range: $0.21 to $0.25
• 50-Day Range: $0.22 to $0.46
• 52-Week Range: $0.21 to $2.88
• Volume: 3.48 million shs
• Average Volume: 1.83 million shs
• Market Capitalization: $7.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Moderate Buy

Senti Biosciences Stock Analysis - MarketRank™

Senti Biosciences scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Senti Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Senti Biosciences has a consensus price target of $9.00, representing about 3,901.8% upside from its current price of $0.22.

Amount of Analyst Coverage

Senti Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Senti Biosciences are expected to grow in the coming year, from ($1.53) to ($0.94) per share.

Price to Book Value per Share Ratio

Senti Biosciences has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.61% of the float of Senti Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Senti Biosciences has a short interest ratio ("days to cover") of 0.25, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Senti Biosciences has recently decreased by 4.63%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Senti Biosciences does not currently pay a dividend.

Dividend Growth

Senti Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Senti Biosciences has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

Search Interest

3 people have searched for SNTI on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Senti Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.12% of the stock of Senti Biosciences is held by insiders.

Percentage Held by Institutions

25.70% of the stock of Senti Biosciences is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SNTI
• CIK: 1854270
• Web: www.sentibio.com
• Phone: 650-239-2030
• Fax: N/A
• Employees: 39
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Senti Biosciences: $9.00
• High Price Target: $12.00
• Low Price Target: $6.00
• Potential Upside/Downside: +3,901.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.44 million
• Net Margins: N/A
• Pretax Margin: -90,116.36%
• Return on Equity: -1,629.80%
• Return on Assets: -119.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.83
• Quick Ratio: 0.83

Sales & Book Value

• Annual Sales: $20 thousand
• Price / Sales: 350.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.18 per share
• Price / Book: 1.25

Miscellaneous

• Outstanding Shares: 31,150,000
• Free Float: 30,173,000
• Market Cap: $7.01 million
• Optionable: Not Optionable
• Beta: 2.21